

SEQUENCE LISTING

<110> AVENTIS PHARMA S.A.

<120> HYBRID PROMOTERS

<130> PPAR INFLAMMATION

<140>

<141>

<160> 7

<170> PatentIn Ver. 2.1

<210> 1

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 1

caaaactagg tcaaaggtca

20

<210> 2

<211> 38

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 2

caaaactagg tcaaagggtca aaactagggtc aaagggtca

38

<210> 3

<211> 41

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 3

caaaactagg tcaaagggtca tcaaaactag gtcaaagggtc a

41

<210> 4

<211> 52

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 4

caaaactagg tcaaagggtca tgtcttagg cccaaaacta ggtcaaagggt ca

52

<210> 5

<211> 271

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: fragment of the PLA2s promoter

<400> 5

```
cgcggcacaaa ctgcctgaaa tgtgtttttg catcagctac tgacacgtaa gggttcccaa 60
tcctcaactc tgtcctgcca gctgatgagg ggaaggaaag ggattaccta ggggtatggg 120
cgaccaatcc tgagtcacc aactgaccac gcccatcccc agccttgtgc ctcacctacc 180
cccaacctcc cagagggagc agctatttaa ggggagcagg agtgcagAAC aaacaagacg 240
gcctggggat acaactctgg agtcctctga g 271
```

<210> 6

<211> 332

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description/PPRE/PLA2s hybrid promoter

<400> 6

```
gtaccaattc gacaaaacta ggtcaaagg catcaaaact aggtcaaagg tcaaattcga 60
acgcggcaaaa actgcctgaa atgtgttttg gcatcagcta ctgacacgta aggtttccca 120
atcctcaact ctgtcctgcc agctgatgag gggaaggaaa gggattacct aggggtatgg 180
gcgaccaatc ctgagtcacc caactgacca cgcccatccc cagccttgtg cctcacctac 240
cccaacctcc ccagagggag cagctattta aggggagcag gagtgcagaa caacaagac 300
ggcctgggga tacaactctg gagtcctctg ag 332
```

<210> 7

<211> 944

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: sequence conferring specificity of expression

<400> 7

tgccggcctc gcggtgagcc ctgateccgc tcggggctcc ccagtcgctg gtgctgctga 60
cgctgctcat cgccgcgggc ctacgggtgtc agggccagga tgcccgtgtaag tcgcccgcgcg 120
ccccctgccta cttccctgac ttgtgacctt ttctctccta ctccctcccc caagtactag 180
gatcccccta gagcttgagc atctgggatt ggcagcgatg gcttccagat gggctgaaac 240
cctgcccgtg tttattttaa ctgggttcctc gtggagagct gtgaatcggg ctctgtatgc 300
gcttgagaaa agccccattc atgagaggca agggccagtg ggtcccccaa ctccccgacc 360
ccccctctccc acaatgcaca gcctccccgc cctcatcccc cccccacccc ccgtgcccgc 420
ctgccgccac cttcagatcg atctgggatt ggcagcgatg gcttccagat gggctgaaac 480
cctgcccgtg tttattttaa ctgggttcctc gtggagagct gtgaatcggg ctctgtatgc 540
gcttgagaaa agccccattc atgagaggca agggccagtg ggtcccccaa ctccccgacc 600
ccccctctccc acaatgcaca gcctccccgc cctcatcccc cccccacccc ccgtgcccgc 660
cctgcccgtg cctccagatc tccagctaga ggatctgcga ctctagggtt cgaaatcgat 720
aagccaagct ctagtggatc ccccggtgtg cagatctgta gggcgcagta gtccagggtt 780
tccttgatga tgtcatactt atcctgtccc ttttttttcc acagctcgcg gttgaggaca 840
aactcttcgc ggtctttcca gtggggatcg acggtatcga taagcttgat gatctgtgac 900
atggcggatc ccgtcgtttt acaacgtcgt gactgggaaa accc 944